|
Primaquine
drug data and news
Primaquine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Primaquine
|
| Brand Names/Synonyms |
Neo-Quipenyl; None; PRIMAQUINE; Primachin; Primaquine |
| Indication |
Malaria;Pneumonia with pneumocystis carinii |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Primaquine is an antimalarial agent and is the essential co-drug with chloroquine in treating all cases of malaria. In the blood, malaria parasites break down a part of the red blood cells known as haemoglobin. When this happens haemoglobin is divided into two parts; haem and globin. Haem is toxic to the malaria parasite. To prevent it from being damaged, the malaria parasite produces an chemical which converts the toxic haem into a non-toxic product. Primaquine acts by interfering with a part of the parasite (mitochondria) that is responsible for supplying it with energy. Without energy the parasite dies. This stops the infection from continuing and allows the person to recover. Primaquine kills the intrahepatic form of Plasmodium vivax and Plasmodium ovale, and thereby prevents the development of the erythrocytic forms that are responsible for relapses (it also kills gametocytes). Primaquine is not used in the prevention of malaria, only in the treatment. It has insignificant activity against the asexual blood forms of the parasite and therefore it is always used in conjunction with a blood schizonticide and never as a single agent. Primaquine has gametocytocidal activity against all plasmodia, including P. falciparum. |
| Mechanism Of Action |
Primaquine's mechanism of action is not well understood. It may be acting by generating reactive oxygen species or by interfering with the electron transport in the parasite. |
Primaquine News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
TABLET |
| Drug_Category |
Antimalarials; ATC:P01BA03 |
| Absorption |
Not Available |
| Interactions |
Not Available |
| Toxicity |
Not Available |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine |
| Chemical Formula |
C15H21N3O |
| Molecular Weight |
259.347 g/mol |
| Smiles String |
CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2 |
| Melting Point |
< 25 °C |
| Water Solubility |
Not Available |
| State |
Solid |
| LogP/Hphobicity |
2.145 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Not Available |
| Half Life |
3.7-7.4 hours) |
| Protein Binding [%] |
Not Available |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
http://www.drugs.com/cons/Primaquine.html |
| Drug Type |
Approved Drug |
| Accession No |
APRD00604 |
| CAS Registry Number |
90-34-6 |
| KEGG Compound ID |
C07627 |
| PubChem ID |
SID:9829 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
2017776
|
|
|
